menu
    • menu
    [{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"DHODH","graph1":"Immunology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"DHODH","graph1":"Immunology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Lacosamide","moa":"Sodium channel alpha subunits","graph1":"Neurology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Bilastine","moa":"H1 receptor","graph1":"Immunology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"OnDosis","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"GERMANY","productType":"Small molecule","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Tiefenbacher Group \/ OnDosis","highestDevelopmentStatusID":"1","companyTruncated":"Tiefenbacher Group \/ OnDosis"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Abiraterone Acetate","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Bilastine","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Orally Disintegrating","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Apremilast","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Apixaban","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Vildagliptin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rivaroxaban","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"},{"orgOrder":0,"company":"Tiefenbacher Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Teriflunomide","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Tiefenbacher Group","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Tiefenbacher Group \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Tiefenbacher Group \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Tiefenbacher Group

    Menu

    Tiefenbacher Group

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Tiefenbacher Group

                            Germany
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

                            Lead Product(s) : Rivaroxaban

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tiefenbacher Pharmaceuticals Prepares Launch of the Anticoagulant Rivaroxaban

                            Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.

                            Brand Name : Xarelto-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 09, 2024

                            Lead Product(s) : Rivaroxaban

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Tiefenbacher Compnay Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Tiefenbacher Group

                            Germany
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

                            Lead Product(s) : Rivaroxaban

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tiefenbacher Pharmaceuticals Successfully Launches the Anticoagulant Rivaroxaban on Day One in Canada

                            Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.

                            Brand Name : Xarelto-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 16, 2023

                            Lead Product(s) : Rivaroxaban

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Tiefenbacher Compnay Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Tiefenbacher Group

                            Germany
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

                            Lead Product(s) : Teriflunomide

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tiefenbacher Pharmaceuticals Successfully Launches the Generic Version of Teriflunomide in more than 20 Europe...

                            Details : Aubagio-Generic (teriflunomide) is a USFDA approved pyrimidine synthesis inhibitor which is indicated for the treatment of patients with relapsing forms of multiple sclerosis.

                            Brand Name : Aubagio-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 27, 2023

                            Lead Product(s) : Teriflunomide

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Tiefenbacher Compnay Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Tiefenbacher Group

                            Germany
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tiefenbacher Pharmaceuticals Successfully Launches the Antihistamine Bilastine for A Market Entry as Over-the-...

                            Details : Bilastine Tiefenbacher (Bilastine) is a histamine H1 receptor inverse agonist, small molecule drug candidate which is indicated for the treatment of allergic rhino-conjunctivitis & urticaria.

                            Brand Name : Bilastine Tiefenbacher

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 14, 2023

                            Lead Product(s) : Bilastine

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Tiefenbacher Compnay Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Tiefenbacher Group

                            Germany
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tiefenbacher Pharmaceuticals Successfully Launches Generic Version of The Psoriasis Medication Apremilast in C...

                            Details : Otezla-Generic (apremilast) is an inhibitor of phosphodiesterase 4 (PDE4). It is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers.

                            Brand Name : Otezla-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 01, 2022

                            Lead Product(s) : Apremilast

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Tiefenbacher Compnay Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Tiefenbacher Group

                            Germany
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

                            Lead Product(s) : Abiraterone Acetate,Prednisolone

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches Generic Versions of The Prostate Cancer ...

                            Details : Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 17, 2022

                            Lead Product(s) : Abiraterone Acetate,Prednisolone

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Tiefenbacher Compnay Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Tiefenbacher Group

                            Germany
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

                            Lead Product(s) : Apixaban

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tiefenbacher Pharmaceuticals Successfully Launches Generic Version of The Anticoagulant Medicine Apixaban in C...

                            Details : Apixaban Tiefenbacher (apixaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

                            Brand Name : Apixaban Tiefenbacher

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 20, 2022

                            Lead Product(s) : Apixaban

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Tiefenbacher Compnay Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Tiefenbacher Group

                            Germany
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

                            Lead Product(s) : Vildagliptin,Metformin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tiefenbacher Pharmaceuticals Successfully Launches Generic Version of The Diabetes Medicine Vildagliptin and V...

                            Details : Vildagliptin/Metformin generic version launched in Africa market, the drug ais a diabetes medicine that are used to control the blood glucose (sugar) in adults with type 2 diabetes, by inhibiting DPP-4.

                            Brand Name : Vildagliptin-Metformin-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 08, 2022

                            Lead Product(s) : Vildagliptin,Metformin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Tiefenbacher Compnay Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Tiefenbacher Group

                            Germany
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

                            Lead Product(s) : Rivaroxaban

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Tiefenbacher Pharmaceuticals Expands the Launch of The Anticoagulant Medicine Rivaroxaban to Central America a...

                            Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.

                            Brand Name : Xarelto-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 15, 2022

                            Lead Product(s) : Rivaroxaban

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Tiefenbacher Compnay Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Tiefenbacher Group

                            Germany
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothWe are the TIEFENBACHER GROUP, Health Pioneers since 1963.

                            Lead Product(s) : Teriflunomide

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Market Launch: Tiefenbacher Pharmaceuticals Successfully Launches First Generic Version of The Multiple Sc...

                            Details : Teriflunomide is a pyrimidine synthesis inhibitor with anti-inflammatory and immunomodulatory properties used to treat patients with the relapsing-remitting form of multiple sclerosis.

                            Brand Name : Teriflunomide-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 01, 2022

                            Lead Product(s) : Teriflunomide

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            Tiefenbacher Compnay Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth